Could This Under-the-Radar Biotech Piggyback on Gilead's Remdesivir Success?
Only one drug has thus far demonstrated the potential to be safe and effective at treating novel coronavirus disease COVID-19 in statistically valid clinical testing. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), even said that Gilead Sciences' (NASDAQ: GILD) remdesivir will be "the standard of care" for treating COVID-19. However, Fauci also stated publicly that remdesivir is only "the first step in what we project will be better and better drugs coming along."
Combinations of drugs sometimes referred to as cocktail therapies have been key in treating other serious viral diseases. Gilead itself has achieved impressive results in treating HIV and hepatitis C using therapies that combine more than one drug.
It's quite possible that this approach could prove to be effective in treating COVID-19. A small drugmaker, BioSig Technologies' (NASDAQ:BGSM) subsidiary ViralClear Pharmaceuticals, thinks that it has an experimental drug that appears to hold promise in fighting COVID-19 in combination with remdesivir. Could this under-the-radar biotech piggyback on Gilead's success?
Source Fool.com
